Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 11;1(1):CD012967.
doi: 10.1002/14651858.CD012967.pub2.

Alpha-lipoic acid for diabetic peripheral neuropathy

Cristian Baicus  1 , Adrian Purcarea  2   3 , Erik von Elm  4 , Caterina Delcea  1 , Florentina L Furtunescu  5
Affiliations

Alpha-lipoic acid for diabetic peripheral neuropathy

Cristian Baicus et al. Cochrane Database Syst Rev. .

Abstract

Background: Diabetic peripheral neuropathy (DPN) is a frequent complication in people living with type 1 or type 2 diabetes. There is currently no effective treatment for DPN. Although alpha-lipoic acid (ALA, also known as thioctic acid) is widely used, there is no consensus about its benefits and harms.

Objectives: To assess the effects of alpha-lipoic acid as a disease-modifying agent in people with diabetic peripheral neuropathy.

Search methods: On 11 September 2022, we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, and two clinical trials registers. We also searched the reference lists of the included studies and relevant review articles for additional references not identified by the electronic searches.

Selection criteria: We included randomised clinical trials (RCTs) that compared ALA with placebo in adults (aged 18 years or older) and that applied the study interventions for at least six months. There were no language restrictions.

Data collection and analysis: We used standard methods expected by Cochrane. The primary outcome was change in neuropathy symptoms expressed as changes in the Total Symptom Score (TSS) at six months after randomisation. Secondary outcomes were change in neuropathy symptoms at six to 12 months and at 12 to 24 months, change in impairment, change in any validated quality of life total score, complications of DPN, and adverse events. We assessed the certainty of the evidence using GRADE.

Main results: Our analysis incorporated three trials involving 816 participants. Two studies included people with type 1 or type 2 diabetes, while one study included only people with type 2 diabetes. The duration of treatment was between six months and 48 months. We judged all studies at high risk of overall bias due to attrition. ALA compared with placebo probably has little or no effect on neuropathy symptoms measured by TSS (lower score is better) after six months (mean difference (MD) -0.16 points, 95% confidence interval (CI) -0.83 to 0.51; 1 study, 330 participants; moderate-certainty evidence). The CI of this effect estimate did not contain the minimal clinically important difference (MCID) of 0.97 points. ALA compared with placebo may have little or no effect on impairment measured by the Neuropathy Impairment Score-Lower Limbs (NIS-LL; lower score is better) after six months (MD -1.02 points, 95% CI -2.93 to 0.89; 1 study, 245 participants; low-certainty evidence). However, we cannot rule out a significant benefit, because the lower limit of the CI surpassed the MCID of 2 points. There is probably little or no difference between ALA and placebo in terms of adverse events leading to cessation of treatment within six months (risk ratio (RR) 1.48, 95% CI 0.50 to 4.35; 3 studies, 1090 participants; moderate-certainty evidence). No studies reported quality of life or complications associated with DPN.

Authors' conclusions: Our analysis suggests that ALA probably has little or no effect on neuropathy symptoms or adverse events at six months, and may have little or no effect on impairment at six months. All the studies were at high risk of attrition bias. Therefore, future RCTs should ensure complete follow-up and transparent reporting of any participants missing from the analyses.

PubMed Disclaimer

Conflict of interest statement

CB: none known. AP: none known. EvE: none known. CD: none known. FLF: none known.

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1: Alpha‐lipoic acid (ALA) versus placebo, Outcome 1: Change in validated symptom score at 6 months
1.2
1.2. Analysis
Comparison 1: Alpha‐lipoic acid (ALA) versus placebo, Outcome 2: Change in validated symptom score at 24 months
1.3
1.3. Analysis
Comparison 1: Alpha‐lipoic acid (ALA) versus placebo, Outcome 3: Change in impairment score at 6 months
1.4
1.4. Analysis
Comparison 1: Alpha‐lipoic acid (ALA) versus placebo, Outcome 4: Change in impairment score at 24 months
1.5
1.5. Analysis
Comparison 1: Alpha‐lipoic acid (ALA) versus placebo, Outcome 5: Adverse events leading to cessation of treatment
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD012967

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Reljanovic 1999 {published data only}
    1. Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Moller W, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Radical Research 1999;31(3):171-9. [DOI: 10.1080/10715769900300721] - DOI - PubMed
Ziegler 1999 {published data only}
    1. Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schütte K, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999;22(8):1296-301. [DOI: 10.2337/diacare.22.8.1296] - DOI - PubMed
Ziegler 2011 {published data only}
    1. Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011;34(9):2054-60. [DOI: 10.2337/dc11-0503] - DOI - PMC - PubMed

References to studies excluded from this review

Medvedeva 2006 {published data only}
    1. Medvedeva LA, Gnezdilov AV, Zagorul'ko OI, Syrovegin AV, Samoilova NV, Slashchuk IuI. Neurometabolic therapy of diabetic neuropathy. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov [i] Vserossiiskoe obshchestvo psikhiatrov 2006;203:71-3. - PubMed

References to studies awaiting assessment

El Nahas 2020 {published data only}
    1. El-Nahas MR, El Kannishy G, Abdelhafez H, Taher I, El Sehrawy A. Oral alpha-lipoic acid adjunctive treatment for symptomatic diabetic peripheral neuropathy: a prospective, double blind, placebo controlled study. 53rd Annual Meeting of the European Association for the Study of Diabetes, 2017, Lisbon. www.easd.org/media-centre/home.html#!resources/oral-alpha-lipoic-acid-ad... (accessed 20 December 2023).
    1. El-Nahas MR, Elkannishy G, Abdelhafez H, Elkhamisy ET, El-Sehrawy AA. Oral alpha lipoic acid treatment for symptomatic diabetic peripheral neuropathy: a randomized double-blinded placebo-controlled study. Endocrine, Metabolic and Immune Disorders Drug Targets 2020;20(9):1531-4. [DOI: 10.2174/1871530320666200506081407] - DOI - PubMed

Additional references

Abubaker 2022
    1. Abubaker SA, Alonazy AM, Abdulrahman A. Effect of alpha-lipoic acid in the treatment of diabetic neuropathy: a systematic review. Cureus 2022;14(6):e25750. - PMC - PubMed
Agrawal 2010
    1. Agrawal Y, Carey JP, Della Santina CC, Schubert MC, Minor LB. Diabetes, vestibular dysfunction, and falls: analyses from the National Health and Nutrition Examination Survey. Otology & Neurotology 2010;31(9):1445-50. [DOI: 10.1097/MAO.0b013e3181f2f035.] - DOI - PubMed
Allen 2014
    1. Allen R, Sharma U, Barlas S. Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy. Journal of Pain Research 2014;7:339-51. - PMC - PubMed
Amin 2016
    1. Amin N, Doupis J. Diabetic foot disease: from the evaluation of the "foot at risk" to the novel diabetic ulcer treatment modalities. World Journal of Diabetes 2016;7(7):153-64. [DOI: 10.4239/wjd.v7.i7.153.] - DOI - PMC - PubMed
Bansal 2006
    1. Bansal V, Kalita J, Misra UK. Diabetic neuropathy. Postgraduate Medical Journal 2006 Feb;82(964):95-100. [DOI: 10.1136/pgmj.2005.036137] - DOI - PMC - PubMed
Bastyr 2005
    1. Bastyr EJ 3rd, Price KL, Bril V, MBBQ Study Group. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clinical Therapeutics 2005;27(8):1278-94. - PubMed
Boulton 1998
    1. Boulton AJ, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management diabetic peripheral neuropathy. Diabetic Medicine 1998;15(6):508-14. - PubMed
Boulton 2005
    1. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. American Diabetes Association. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005;28(4):956-62. [PMID: ] - PubMed
Bredfeldt 2015
    1. Bredfeldt C, Altschuler A, Adams AS, Ports J, Bayliss E. Patient reported outcomes for diabetic peripheral neuropathy. Journal of Diabetes and Its Complications 2015;29(8):1112-8. - PubMed
Brownlee 2005
    1. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54(6):1615–25. - PubMed
Callaghan 2012a
    1. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurology 2012;11(6):521-34. [DOI: 10.1016/S1474-4422(12)70065-0] - DOI - PMC - PubMed
Callaghan 2012b
    1. BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database of Systematic Reviews 2012, Issue 6. Art. No: CD007543. [DOI: 10.1002/14651858.CD007543.pub2] - DOI - PMC - PubMed
Chalk 2007
    1. Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No: CD004572. [DOI: 10.1002/14651858.CD004572.pub2] - DOI - PMC - PubMed
Chen 2013
    1. Chen W, Zhang Y, Li X, Yang G, Liu JP. Chinese herbal medicine for diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No: CD007796. [DOI: 10.1002/14651858.CD007796.pub3] - DOI - PMC - PubMed
Covidence [Computer program]
    1. Covidence. Version accessed 1 May 2018. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.
DCCT 1993
    1. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 1993;329(14):977-86. - PubMed
DCCT 1995
    1. DCCT Research Group. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Annals of Neurology 1995;38(6):869-80. [DOI: 10.1002/ana.410380607] - DOI - PubMed
Duckworth 2009
    1. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. New England Journal of Medicine 2009;360(2):129-39. - PubMed
Dyck 1991
    1. Dyck PJ, Kratz KM, Lehman KA, Karnes JL, Melton LJ 3rd, O'Brien PC, et al. The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 1991;41(6):799-807. - PubMed
Edwards 2008
    1. Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacology & Therapeutics 2008;120(1):1-34. [DOI: 10.1016/j.pharmthera.2008.05.005] - DOI - PMC - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34. - PMC - PubMed
Elafros 2022
    1. Elafros MA, Andersen H, Bennett DL, Savelieff MG, Viswanathan V, Callaghan BC, et al. Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments. Lancet Neurology 2022;21(10):922-36. - PMC - PubMed
Feldman 1997
    1. Feldman EL, Stevens MJ, Greene DA. Pathogenesis of diabetic neuropathy. Clinical Neuroscience 1997;4(6):365-70. - PubMed
Feldman 2017
    1. Feldman EL, Bennett DL, Nave KA, Jensen TS. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron 2017;93(6):1296-313. [DOI: 10.1016/j.neuron.2017.02.005] - DOI - PMC - PubMed
Feldman 2019
    1. Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, et al. Diabetic neuropathy. Nature Reviews Disease Primers 2019;5(1):41. [DOI: 10.1038/s41572-019-0092-1] - DOI - PubMed
Fernyhough 2015
    1. Fernyhough P. Mitochondrial dysfunction in diabetic neuropathy: a series of unfortunate metabolic events. Current Diabetes Reports 2015;15(11):89. [DOI: 10.1007/s11892-015-0671-9] - DOI - PubMed
Gilron 2021
    1. Gilron I, Robb S, Tu D, Holden R, Towheed T, Ziegler D, et al. Double-blind, randomized, placebo-controlled crossover trial of alpha-lipoic acid for the treatment of fibromyalgia pain: the IMPALA trial. Pain 2021;162(2):561-8. - PubMed
Han 2012
    1. Han T, Bai J, Liu W, Hu Y. A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. European Journal of Endocrinology 2012;167(4):465-71. - PubMed
Higgins 2017
    1. Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8: Assessing risk of bias in included studies. In Higgins JP, Altman DG, Sterne JA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane 2017. Available from www.training.cochrane.org/handbook/archive/v5.2.
Higgins 2022
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook/archive/v6.3. - PMC - PubMed
Ibrahim 2017
    1. Ibrahim A. IDF Clinical Practice Recommendation on the Diabetic Foot: a guide for healthcare professionals. Diabetes Research and Clinical Practice 2017;127:285-7. [DOI: 10.1016/j.diabres.2017.04.013] - DOI - PubMed
IDF 2021
    1. International Diabetes Federation. IDF Diabetes Atlas. 10th edition. Brussels: International Diabetes Federation, 2021.
Khanna 1999
    1. Khanna S, Roy S, Packer L, Sen CK. Cytokine-induced glucose uptake in skeletal muscle: redox regulation and the role of alpha-lipoic acid. American Journal of Physiology 1999;276(5 Pt 2):R1327-33. - PubMed
Kim 2013
    1. Kim PJ, Steinberg JS. Complications of the diabetic foot. Endocrinology and Metabolism Clinics of North America 2013;42(4):833-47. [DOI: 10.1016/j.ecl.2013.08.002] - DOI - PubMed
Kolm‐Litty 1998
    1. Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, Schleicher ED. High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. Journal of Clinical Investigation 1998;101(1):160-9. - PMC - PubMed
Low 1997
    1. Low PA, Nickander KK, Tritschler HJ. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 1997;46(Suppl 2):S38-42. - PubMed
Lunn 2014
    1. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No: CD007115. [DOI: 10.1002/14651858.CD007115.pub3] - DOI - PMC - PubMed
Mallik 2014
    1. Mallik S, Kallis C, Lunn MPT, Smith AG. Gangliosides for the treatment of diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews 2014, Issue 3. Art. No: CD011028. [DOI: 10.1002/14651858.CD011028] - DOI
Marangon 1999
    1. Marangon K, Devaraj S, Tirosh O, Packer L, Jialal I. Comparison of the effect of alpha-lipoic acid and alpha-tocopherol supplementation on measures of oxidative stress. Free Radical Biology & Medicine 1999;27(9-10):1114-21. - PubMed
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097] - DOI - PMC - PubMed
Norman 2003
    1. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health‐related quality of life: the remarkable universality of half a standard deviation. Medical Care 2003;41(5):582-92. - PubMed
Packer 1995
    1. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radical Biology & Medicine 1995;19(2):227-50. - PubMed
Peripheral Nerve Society 1995
    1. Peripheral Nerve Society. Diabetic polyneuropathy clinical trials: consensus in controlled report of the peripheral nerve society. Annals of Neurology 1995;38(3):478-82. - PubMed
Petersen 2008
    1. Petersen Shay K, Moreau RF, Smith EJ, Hagen TM. Is alpha-lipoic acid a scavenger of reactive oxygen species in vivo? Evidence for its initiation of stress signaling pathways that promote endogenous antioxidant capacity. IUBMB Life 2008;60(6):362-7. [DOI: 10.1002/iub.40] - DOI - PubMed
Pop‐Busui 2013
    1. Pop-Busui R, Lu J, Mori Brooks M, Albert S, Althouse AD, Escobedo J, et al. Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care 2013;36(10):32-15. [DOI: 10.2337/dc13-0012] - DOI - PMC - PubMed
Pop‐Busui 2017
    1. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017;40(1):136-54. [DOI: 10.2337/dc16-2042] - DOI - PMC - PubMed
Price 2022
    1. Price R, Smith D, Franklin G, Gronseth G, Pignone M, David WS, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary. Report of the AAN Guideline Subcommittee. Neurology 2022;98(1):31-43. [DOI: 10.1212/WNL.0000000000013038] - DOI - PubMed
RevMan 2014 [Computer program]
    1. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rochette 2015
    1. Rochette L, Ghibu S, Muresan A, Vergely C. Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes. Canadian Journal of Physiology and Pharmacology 2015;93(12):1021-7. - PubMed
Rolim 2019
    1. Rolim LC, da Silva EM, Flumignan RL, Abreu MM, Dib SA. Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews 2019, Issue 6. Art. No: CD011265. [DOI: 10.1002/14651858.CD011265.pub2] - DOI - PMC - PubMed
Saarto 2007
    1. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No: CD005454. [DOI: 10.1002/14651858.CD005454.pub2] - DOI - PMC - PubMed
Saeedi 2019
    1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Research and Clinical Practice 2019;157:107843. [DOI: 10.1016/j.diabres.2019.107843] - DOI - PubMed
Snedecor 2014
    1. Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Practice 2014;14(2):167-84. - PubMed
Stavniichuk 2014
    1. Stavniichuk R, Shevalye H, Lupachyk S, Obrosov A, Groves JT, Obrosova IG, et al. Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy. Diabetes Metabolism Research and Reviews 2014;30(8):669-78. [DOI: 10.1002/dmrr.2549] - DOI - PMC - PubMed
Streeper 1997
    1. Streeper RS, Henriksen EJ, Jacob S, Hokama JY, Fogt DL, Tritschler HJ. Differential effects of lipoic acid stereoisomers on glucose metabolism in insulin-resistant skeletal muscle. American Journal of Physiology 1997;273(1 Pt 1):E185-91. - PubMed
Tesfaye 2010
    1. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33(10):2285-93. - PMC - PubMed
Tesfaye 2011
    1. Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA, Baconja M, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes/Metabolism Research and Reviews 2011;27(7):629-38. [DOI: 10.1007/BF00400697] - DOI - PubMed
Uehara 2004
    1. Uehara K, Yamagishi S, Otsuki S, Chin S, Yagihashi S. Effects of polyol pathway hyperactivity on protein kinase C activity, nociceptive peptide expression, and neuronal structure in dorsal root ganglia in diabetic mice. Diabetes 2004;53(12):3239-47. - PubMed
Vincent 2013
    1. Vincent AM, Calabek B, Roberts L, Feldman EL. Biology of diabetic neuropathy. Handbook of Clinical Neurology 2013;115:591-606. [DOI: 10.1016/B978-0-444-52902-2.00034-5] - DOI - PubMed
Vinik 2004
    1. Vinik AI, Mehrabyan A. Diabetic neuropathies. Medical Clinics of North America 2004;88(4):947-99. - PubMed
Wang 2006
    1. Wang Y, Schmeichel AM, Iida H, Schmelzer JD, Low PA. Enhanced inflammatory response via activation of NF-kappaB in acute experimental diabetic neuropathy subjected to ischemia reperfusion injury. Journal of the Neurological Sciences 2006;247(1):47-52. - PubMed
WHO 1999
    1. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus (WHO/NCD/NCS/99.2). Geneva: World Health Organization. apps.who.int/iris/bitstream/10665/66040/1/WHO_NCD_NCS_99.2.pdf 1999.
WHO 2016
    1. World Health Organization. Global Report on Diabetes. 2016. www.who.int/diabetes/global-report/en/ (accessed 22 May 2017).
Xu 2013
    1. Xu Q, Pan J, Yu J, Liu X, Liu L, Zuo X, et al. Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy. Diabetes Research and Clinical Practice 2013;101(2):99-105. [DOI: 10.1016/j.diabres.2013.03.033] - DOI - PubMed
Young 1993
    1. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993;36(2):150-4. - PubMed
Ziegler 2004
    1. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabetic Medicine 2004;21(2):114-21. - PubMed
Ziegler 2006
    1. Ziegler D. Treatment of diabetic polyneuropathy: update. 2006. Annals of the New York Academy of Sciences 2006;1084:250-66. - PubMed
Ziegler 2021a
    1. Ziegler D, Papanas N, Schnell O, Nguyen BD, Nguyen KT, Kulkantrakorn K, et al. Current concepts in the management of diabetic polyneuropathy. Journal of Diabetes Investigation 2021;12(4):464-75. [DOI: 10.1111/jdi.13401] - DOI - PMC - PubMed
Ziegler 2021b
    1. Ziegler D, Keller J, Maier C, Pannek J. Diabetic neuropathy. Experimental and Clinical Endocrinology and Diabetes 2021;129(S 01):S70-S81. [DOI: 10.1055/a-1284-6245] - DOI - PubMed
Ziegler 2022
    1. Ziegler D, Tesfaye S, Spallone V, Gurieva I, Al Kaabi J, Mankovsky B, et al. Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: international expert consensus recommendations. Diabetes Research and Clinical Practice 2022;186:109063. [DOI: 10.1016/j.diabres.2021.109063] - DOI - PubMed

References to other published versions of this review

Baicus 2018
    1. Baicus C, Purcarea A, Elm E, Delcea C, Furtunescu F. Alpha‐lipoic acid for diabetic peripheral neuropathy. Cochrane Database of Systematic Reviews 2018, Issue 2. Art. No: CD012967. [DOI: 10.1002/14651858.CD012967] - DOI - PMC - PubMed

Publication types

LinkOut - more resources